A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis



Status:Recruiting
Conditions:Gastrointestinal
Therapuetic Areas:Gastroenterology
Healthy:No
Age Range:18 - 75
Updated:3/22/2019
Start Date:December 27, 2017
End Date:April 2019
Contact:Nathalie Adda
Email:nadda@enanta.com
Phone:617 607 0705

Use our guide to learn which trials are right for you!

A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)

A randomized, double-blind study to assess the safety, tolerability, PK and efficacy of
EDP-305 in subjects with primary biliary cholangitis


Inclusion Criteria:

- An informed consent document signed and dated by the subject.

- Male and female subjects of any ethnic origin between the ages of 18 and 75 years,
inclusive

- Male or female with a diagnosis of PBC by at least two of the following criteria:

- History of ALP above ULN for at least six months

- Positive Anti-Mitochondrial Antibodies (AMA) titers (>1/40 on immunofluorescence
or M2 positive by enzyme linked immunosorbent assay (ELISA) or positive
PBC-specific antinuclear antibodies)

- For subjects with no documented liver biopsy performed within 2 years, subjects must
undergo a transient elastography (Fibroscan) showing liver stiffness < 14.0 kPA

- Must be on a stable dose of UDCA12-20 mg/kg/day for at least 6 months prior to
Screening or intolerant of UDCA in the opinion of the Investigator (no UDCA for at
least 12 weeks prior to Screening)

- Alkaline Phosphatase (ALP) ≥ 1.67 × ULN and/or total bilirubin >ULN but < 2×ULN (<2.4
mg/dL)

- Subjects must have Screening laboratory values for Hepatitis B surface antigen
(HBsAg), anti-HCV antibodies and HCV RNA negative and Human Immunodeficiency Virus
(HIV) 1 and 2 antibodies (Ab) as seronegative. Note: subjects previously infected by
chronic hepatitis C and treated with direct acting antivirals (DAAs) with sustained
virologic response (SVR) for at least 3 years will be allowed.

- Female subjects of childbearing potential must agree to use two effective methods of
contraception from the date of Screening until 90 days after the last dose of EDP-305.

- All male participants who have not had a vasectomy must use effective contraception
from Day -1 to 90 days after their last dose of study drug.

- Male subjects must agree to refrain from sperm donation from the date of Screening
until 90 days after their last dose of study drug

- Screening body mass index (BMI) of ≥18 kg/m2

- Subject must be willing and able to adhere to the assessments, visit schedule,
prohibitions and restrictions, as described in this protocol

Exclusion Criteria:

- Laboratory Screening Results:

- AST >5 x ULN

- ALT >5 x ULN

- Patients with Gilbert's syndrome will not be allowed due to interpretability of
bilirubin levels

- Total white blood cells (WBC) <3000 cells/mm3

- Absolute neutrophil count (ANC) <1500 cells/mm3

- Platelet count <140,000/mm3

- Prothrombin time (international normalized ratio, INR) >1.2

- Serum creatinine >2 mg/dL or creatinine clearance <60 mL/min (based on
Cockroft-Gault Method)

- Suspected to have relevant nonalcoholic fatty liver disease (NAFLD) as based on the
judgment of the Investigator at Screening

- Use of immunosuppressants known to have an effect on the liver of patients with PBC
(eg, colchicine, methotrexate, azathioprine, or systemic steroids) in the three months
preceding screening

- Current use of fibrates, including fenofibrates. Note: Subjects who discontinued
fibrates for at least 3 months before Screening can participate

- Use of an experimental treatment for PBC within the past 6 months

- Co-existing liver or biliary diseases, such as primary sclerosing cholangitis,
choledocholithiasis, acute or chronic hepatitis, autoimmune hepatitis, alcoholic liver
disease, nonalcoholic steatohepatitis (NASH), acute infection of bile duct system or
gall bladder, history of gastrointestinal bleeding (secondary to portal hypertension),
cirrhosis, cholangiocarcinoma diagnosed or suspected liver cancers

- Cirrhosis with or without complications, including history or presence of: spontaneous
bacterial peritonitis, hepatocellular carcinoma

- Hepatorenal syndrome (type I or II) or Screening serum creatinine > 2 mg/dL (178
μmol/L)

- Prior variceal hemorrhage, uncontrolled encephalopathy, Child-Pugh Class A, B and C,
esophageal varices, or refractory ascites within the previous 6 months of Screening
(defined as date informed consent signed)

- Medical conditions that may cause nonhepatic increases in ALP (e.g., Paget's disease)

- Use of a new statin regimen from Screening and throughout study duration. NOTE:
Subjects on a stable dose of statins for at least 3 months prior to Screening are
allowed. No dose modification during the study will be allowed.

- Use of immunosuppressants (eg, systemic corticosteroids) for more than 2 consecutive
weeks in duration within 1 year prior to Screening.
We found this trial at
38
sites
Manhasset, New York 11030
Principal Investigator: David Bernstein
?
mi
from
Manhasset, NY
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
Principal Investigator: Daniel Pratt
?
mi
from
Boston, MA
Click here to add this to my saved trials
330 Brookline Ave
Boston, Massachusetts 02215
617-667-7000
Principal Investigator: Alan Bonder
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
?
mi
from
Boston, MA
Click here to add this to my saved trials
8700 Beverly Blvd # 8211
Los Angeles, California 90048
(1-800-233-2771)
Principal Investigator: Ayoub Walid
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Seattle, Washington 98104
(206) 543-2100
Principal Investigator: Charles Landis
Univ of Washington Founded in 1861 by a private gift of 10 acres in what...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Atlanta, Georgia
Principal Investigator: Gary Richter
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
345 Saint Paul Place
Baltimore, Maryland 21202
Principal Investigator: Paul Thuluvath
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Bronx, New York 10467
Principal Investigator: Harmit Kalia
?
mi
from
Bronx, NY
Click here to add this to my saved trials
Catonsville, Maryland 21228
Principal Investigator: Natarajan Ravendhran
?
mi
from
Catonsville, MD
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Principal Investigator: Steven Flamm
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Clearwater, Florida 33756
Principal Investigator: Lawrence Michael Weiss
?
mi
from
Clearwater, FL
Click here to add this to my saved trials
Coronado, California 92118
Principal Investigator: Tarek Hassanein
?
mi
from
Coronado, CA
Click here to add this to my saved trials
Dallas, Texas 75203
Principal Investigator: Maisha Barnes
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Dallas, Texas 76104
Principal Investigator: Manjushree Gautam
?
mi
from
Dallas, TX
Click here to add this to my saved trials
2799 W Grand Blvd
Detroit, Michigan 48202
(313) 916-2600
Principal Investigator: Reena Salgia
Henry Ford Hospital Founded in 1915 by auto pioneer Henry Ford and now one of...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Dothan, Alabama 36305
Principal Investigator: Scott Sarrels
?
mi
from
Dothan, AL
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: John Vierling
?
mi
from
Houston, TX
Click here to add this to my saved trials
Inverness, Florida 34452
Principal Investigator: Paul Hellstern
?
mi
from
Inverness, FL
Click here to add this to my saved trials
200 Hawkins Dr,
Iowa City, Iowa 52242
866-452-8507
Principal Investigator: Antonio Sanchez
University of Iowa Hospitals and Clinics University of Iowa Hospitals and Clinics—recognized as one of...
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
Kingswood, New South Wales 2747
Principal Investigator: Martin Weltman
?
mi
from
Kingswood,
Click here to add this to my saved trials
1 Medical Center Dr
Lebanon, New Hampshire 03756
 (603) 650-5000
Principal Investigator: Mary Drinane
Dartmouth Hitchcock Medical Center Dartmouth-Hitchcock is a national leader in patient-centered health care and building...
?
mi
from
Lebanon, NH
Click here to add this to my saved trials
Little Rock, Arkansas 72205
Principal Investigator: Alonzo Williams
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
Little Rock, Arkansas 76012
Principal Investigator: Reem Ghalib
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
Miami, Florida 33136
Principal Investigator: Cynthia Levy
?
mi
from
Miami, FL
Click here to add this to my saved trials
New York, New York 10016
Principal Investigator: Ira Jacobson
?
mi
from
New York, NY
Click here to add this to my saved trials
New York, New York 10021
Principal Investigator: Sonal Kumar
?
mi
from
New York, NY
Click here to add this to my saved trials
New York, New York 10016
Principal Investigator: Hillel Tobias
?
mi
from
New York, NY
Click here to add this to my saved trials
1428 Madison Ave
New York, New York 10029
(212) 241-6500
Principal Investigator: Douglas Dieterich
Icahn School of Medicine at Mount Sinai Icahn School of Medicine at Mount Sinai is...
?
mi
from
New York, NY
Click here to add this to my saved trials
Omaha, Nebraska 68124
Principal Investigator: Sandeep Mukherjee
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Pasadena, California 91105
Principal Investigator: Edward Mena
?
mi
from
Pasadena, CA
Click here to add this to my saved trials
301 South Fair Oaks Avenue
Pasadena, California 91105
Principal Investigator: Edward Mena
?
mi
from
Pasadena, CA
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15213
Principal Investigator: Mordechai Rabinovitz
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Rialto, California 92377
Principal Investigator: Zeid Kayali, MD
?
mi
from
Rialto, CA
Click here to add this to my saved trials
Richmond, Virginia 23602
Principal Investigator: Mitchell Shiffman
?
mi
from
Richmond, VA
Click here to add this to my saved trials
San Antonio, Texas 78215
Principal Investigator: Eric Lawitz, MD
Phone: 210-253-3426
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
45 Castro Street
San Francisco, California 94114
(415) 600-6000
Principal Investigator: Kidist Yimam
California Pacific Medical Center California Pacific Medical Center is one of the largest private, not-for-profit,...
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
Seattle, Washington 98122
Principal Investigator: Kris Kowdley
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Shreveport, Louisiana 71103
Principal Investigator: Humberto Aguilar
?
mi
from
Shreveport, LA
Click here to add this to my saved trials